- The disease
- Day hospitals are licensed facilities that deliver same-day surgical and procedural care, meaning patients are admitted and discharged on the same day without an overnight stay. Procedures performed in this setting typically include endoscopy, minor surgery, and other low-to-medium complexity interventions. The model is distinct from acute inpatient hospital care and is reimbursed through a combination of private health insurance and patient out-of-pocket contributions in Australia.
- What the asset is trying to do
- Montserrat Day Hospitals is an operating division of Healius Limited (ASX: HLS) that runs a network of day hospital facilities across Australia. The business generates revenue by providing procedural capacity to specialist medical practitioners and their patients, rather than by developing or selling a drug or medical device. There is no novel therapeutic mechanism to describe for this asset.
- What the trial is measuring, and why it matters
- As a commercial, approved healthcare services business, Montserrat Day Hospitals is not evaluated through a clinical trial with formal endpoints. Performance is assessed through conventional operating metrics such as procedure volumes, facility utilisation, revenue, and earnings before interest, tax, depreciation, and amortisation (EBITDA).
- Efficacy benchmarks in this setting
- There are no clinical trial efficacy benchmarks applicable to a day hospital services business. No drug response rates or survival figures are relevant to this asset.
- Commercial context
- Day hospital facilities in Australia operate under state-based licensing regimes and are recognised providers under the private health insurance framework administered by the Australian Prudential Regulation Authority (APRA). Montserrat Day Hospitals is a named operating segment within Healius Limited, which is listed on the ASX (ticker: HLS). Recent ASX announcements from Healius disclose a series of substantial holder changes involving Macquarie Group (MQG) between May and June 2026 (per ASX substantial holder notices dated 2026-05-15 through 2026-06-15).